Consultation on proposed commitments in respect of Vifor Pharma’s supply of intravenous iron
Consultation description
The Competition and Markets Authority (CMA) invites views on commitments offered by Vifor Pharma, in relation to our investigation into its conduct in the market for the supply of high-dose intravenous iron, under the Chapter II prohibition of the Competition Act 1998.
Our investigation relates to concerns that Vifor Pharma made potentially misleading claims about a competitor’s intravenous iron treatment, Monofer (supplied by Pharmacosmos), as compared to Vifor Pharma’s own product, Ferinject.
We provisionally consider that the proposed commitments address the competition concerns we identified, for the reasons set out in the Notice of Intention to Accept Commitments. Therefore, subject to consultation responses, we propose to accept the proposed commitments.
To comment on the commitments, email your response to [email protected] with the subject line ‘Case 51377 – Response to Vifor Proposed Commitments’.
More information can be found on the investigation into Vifor Pharma case page.